Telehealth company Ro has partnered with pharmaceutical company Eli Lilly to expand distribution of single-dose vials of its GLP-1 weight loss medication Zepbound at reduced prices.
Through this partnership, Ro's platform will offer 2.5 mg vials of Zepbound for USD 399 per month and five mg vials for USD 549 per month, matching prices previously only available through LillyDirect. The collaboration allows Lilly to reach Ro's established network of 1.5 million patients, while Ro gains the ability to offer FDA-approved Zepbound instead of solely relying on compounded versions of the medication.
Analyst QuickTake: In May , Ro launched an interactive tool called the "GLP-1 Supply Tracker" to offer patients timely information regarding GLP-1 drug availability in their local areas. With this partnership with Eli Lilly, Ro furthers its ability to offer GLP-1 medications while furthering its market presence in the weight loss medication vertical.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.